{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:52:58Z","timestamp":1790268778733,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.tube.2010.03.003","type":"journal-article","created":{"date-parts":[[2010,4,10]],"date-time":"2010-04-10T04:34:24Z","timestamp":1270874064000},"page":"162-167","source":"Crossref","is-referenced-by-count":69,"title":["Tuberculosis drug development: Progress, challenges, and the road ahead"],"prefix":"10.1016","volume":"90","author":[{"given":"Ann M.","family":"Ginsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2010.03.003_bib1","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1371\/journal.pmed.0040344","article-title":"Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model","volume":"4","author":"Rosenthal","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.tube.2010.03.003_bib2a","unstructured":"St. George\u2019s Hospital Medical School, An international multicentre controlled clinical trial to evaluate high dose RIFApentine and a QUINolone in the treatment of pulmonary tuberculosis high dose RIFApentine high dose RIFApentine and a QUINolone in the treatment of pulmonary tuberculosis (RIFAQUIN), ISRCTN44153044, http:\/\/apps.who.int\/trialsearch\/default.aspx."},{"key":"10.1016\/j.tube.2010.03.003_bib2b","unstructured":"APRIORI, Pharmacokinetics and pharmacodynamics of high versus standard dose rifampicin in patients with pulmonary tuberculosis (High RIF), clinicaltrials.gov identifier NCT00760149."},{"key":"10.1016\/j.tube.2010.03.003_bib2c","unstructured":"Johns Hopkins University, Study of daily rifapentine for pulmonary tuberculosis, clinicaltrials.gov identifier NCT00814671."},{"key":"10.1016\/j.tube.2010.03.003_bib2d","unstructured":"U.S. Centers for Disease Control and Prevention, TBTC Study 29: rifapentine during intensive phase tuberculosis (TB) treatment, clinicaltrials.gov identifier NCT00694629."},{"key":"10.1016\/j.tube.2010.03.003_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00005792-199911000-00001","article-title":"Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions","volume":"78","author":"Martinez","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.tube.2010.03.003_bib4","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1128\/AAC.00554-08","article-title":"Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations","volume":"52","author":"Dooley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.03.003_bib5","unstructured":"Gatifloxacin: clinicaltrials.gov identifier: NCT00216385."},{"key":"10.1016\/j.tube.2010.03.003_bib6","unstructured":"Moxifloxacin: clinicaltrials.gov idenitifier: NCT00864383."},{"issue":"Suppl. 1","key":"10.1016\/j.tube.2010.03.003_bib7","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: a review of safety and tolerability","volume":"59","author":"Vinh","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.tube.2010.03.003_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/648675","article-title":"Linezolid in the treatment of multidrug-resistant tuberculosis","volume":"50","author":"Schecter","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2010.03.003_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1183\/09031936.00009509","article-title":"A retrospective TBNET assessment of linezolid safety, tolerability and\u00a0efficacy in multidrug-resistant tuberculosis","volume":"34","author":"Migliori","year":"2009","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.tube.2010.03.003_bib10","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.200806-892OC","article-title":"Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis","volume":"178","author":"Dietze","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2010.03.003_bib11","unstructured":"U.S. National Institutes of Health, A phase 2a, randomized, 2-Arm, open-label, clinical trial of the efficacy of linezolid combined with antituberculous therapy in subjects with Extensively Drug-Resistant (XDR) pulmonary tuberculosis, http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00727844."},{"key":"10.1016\/j.tube.2010.03.003_bib12","unstructured":"TBTC Study 30: A Phase I\/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-Drug Resistant Tuberculosis. clinicaltrials.gov\/ct2\/show\/NCT00664313."},{"issue":"4","key":"10.1016\/j.tube.2010.03.003_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1164\/rccm.200904-0611OC","article-title":"Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis","volume":"180","author":"Williams","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2010.03.003_bib14","unstructured":"Clinicaltrials.gov identifier: NCT00871949."},{"key":"10.1016\/j.tube.2010.03.003_bib15","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.1164571","article-title":"PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release","volume":"322","author":"Singh","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.tube.2010.03.003_bib16","unstructured":"Clinicaltrials.gov identifier: NCT00685360."},{"key":"10.1016\/j.tube.2010.03.003_bib17","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/AAC.00106-09","article-title":"Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.tube.2010.03.003_bib18","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1128\/AAC.00112-09","article-title":"Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.03.003_bib19","unstructured":"Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, et\u00a0al. The safety, tolerability and early bactericidal activity and pharmacokinetics of PA824 in previously untreated, uncomplicated, sputum smear-positive pulmonary tuberculosis patients, Antimicrob Agents Chemother, in press."},{"key":"10.1016\/j.tube.2010.03.003_bib20","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug resistant tuberculsosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2010.03.003_bib21","doi-asserted-by":"crossref","first-page":"40174","DOI":"10.1074\/jbc.M406796200","article-title":"The transcriptional responses of M. tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action","volume":"279","author":"Boshoff","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tube.2010.03.003_bib22","unstructured":"Horwith G, Einck L, Protopopova M, Nacy C. Abstract of presentation, In: 45th IDSA annual meeting, San Diego, CA; Oct 4\u20137, 2007."},{"key":"10.1016\/j.tube.2010.03.003_bib23","unstructured":"Clinicaltrials.gov identifier: NCT00866190."},{"key":"10.1016\/j.tube.2010.03.003_bib24","unstructured":"Personal communication: Dr. Rajender Kamboj, President, Novel Drug Discovery & Development, Lupin Limited, Pune, India to Stop TB Partnership Working Group on New Drugs, 30 September 2008."},{"key":"10.1016\/j.tube.2010.03.003_bib25","doi-asserted-by":"crossref","first-page":"a2052","DOI":"10.1136\/bmj.a2052","article-title":"South African BCG trial team. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial","volume":"337","author":"Hawkridge","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.tube.2010.03.003_bib26","first-page":"1367","article-title":"Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes?","volume":"13","author":"van Niekerk","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.tube.2010.03.003_bib27","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British medical research council tuberculosis units, 1946\u20131986, with relevant subsequent publications","volume":"3","author":"Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.tube.2010.03.003_bib28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ccm.2009.08.009","article-title":"Advances in immunotherapy for tuberculosis treatment","volume":"30","author":"Churchyard","year":"2009","journal-title":"Clin Chest Med"},{"issue":"9","key":"10.1016\/j.tube.2010.03.003_bib29","doi-asserted-by":"crossref","first-page":"e6984","DOI":"10.1371\/journal.pone.0006984","article-title":"Immunomodulation with recombinant interferon-\u03b31b in pulmonary tuberculosis","volume":"4","author":"Dawson","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2010.03.003_bib30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bmj.2.4582.769","article-title":"Streptomycin treatment of pulmonary tuberculosis","volume":"2","author":"Medical Research Council","year":"1948","journal-title":"BMJ"},{"key":"10.1016\/j.tube.2010.03.003_bib31","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/bmj.1.4769.1157","article-title":"The prevention of streptomycin resistance by combined chemotherapy","volume":"1","author":"Medical Research Council","year":"1952","journal-title":"BMJ"},{"key":"10.1016\/j.tube.2010.03.003_bib32","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/ajrccm\/147.4.1062","article-title":"Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months","volume":"147","author":"Mitchison","year":"1993","journal-title":"Am Rev Respir Dis"},{"issue":"7","key":"10.1016\/j.tube.2010.03.003_bib33","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.01550-06","article-title":"Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients","volume":"51","author":"Ruslami","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.03.003_bib34","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.03.003_bib35","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Rifapentine and isoniazid once a week versus rifampin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.tube.2010.03.003_bib36","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin mono-resistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid","volume":"353","author":"Vernon","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.tube.2010.03.003_bib37","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1164\/ajrccm.150.5.7952564","article-title":"Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice","volume":"150","author":"Chapuis","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"25","key":"10.1016\/j.tube.2010.03.003_bib38","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1056\/NEJMc066207","article-title":"Gatifloxacin and dysglycemia in older adults","volume":"354","author":"Yadav","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2010.03.003_bib39","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJMoa055191","article-title":"Outpatient gatifloxacin therapy and dysglycemia in older adults","volume":"354","author":"Park-Wyllie","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.tube.2010.03.003_bib40","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/AAC.01326-06","article-title":"R63; Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs","volume":"51","author":"Nikonenko","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.tube.2010.03.003_bib41","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jac\/dki319","article-title":"Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1, 2-ethylenediamines","volume":"56","author":"Protopopova","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2010.03.003_bib42","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1128\/AAC.42.11.3035","article-title":"Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic M. tuberculosis strains","volume":"42","author":"Deidda","year":"1998","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979210000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979210000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:01:21Z","timestamp":1559001681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979210000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S1472979210000247"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2010.03.003","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}